Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03097770 |
Recruitment Status :
Completed
First Posted : March 31, 2017
Last Update Posted : September 2, 2020
|
Sponsor:
Chinese PLA General Hospital
Information provided by (Responsible Party):
Han weidong, Chinese PLA General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | May 10, 2019 |
Actual Study Completion Date : | January 31, 2020 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):